Peptide-drug conjugate demonstrates antitumour activity
Cybrexa Therapeutics has dosed the first patient in a Phase II trial of its peptide-drug conjugate (PDC) CBX-12 in ovarian cancer.
The primary target patient population for the study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents.
CBX-12 is a first-in-class PDC that uses Cybrexa’s proprietary alphalex technology to enhance the delivery of exatecan, a potent, established topoisomerase 1 (TOP1) inhibitor, directly to tumour cells while sparing healthy tissue.
The study initiation follows positive Phase I study results, which showed a 40% response rate in TOP1-naïve ovarian cancer patients, in addition to activity across five other solid tumour types and a favourable safety profile.
Per Hellsund, President and Chief Executive Officer of Cybrexa, said: “CBX-12 recently demonstrated significant antitumor activity, broad application potential, and a favourable safety profile in a Phase I study, including encouraging response rates in TOP1-naïve ovarian and breast cancer patients. We are particularly excited about the potential for CBX-12 not only as a standalone treatment but also as a promising candidate for future combination therapies and look forward to its continued advancement in this and additional Phase II studies in solid tumours, which are planned for 2025.”
Cybrexa plans an additional Phase II study of CBX-12 in colorectal cancer in 2025 in collaboration with the National Cancer Institute (NCI), as well as other Phase II studies evaluating CBX-12 as a monotherapy and in combination across a range of solid tumours.
The company’s broader pipeline includes CBX-15, which is expected to enter the clinic in 2025 for the treatment of solid tumours using MMAE (monomethyl auristatin E) as its payload.
Unlike antibody-drug conjugates, CBX-12 does not rely on antigen expression for targeting but rather uses a pH-low insertion peptide (pHLIP) to selectively deliver its payload into the cytoplasm of cancer cells.
Diana Spencer, Senior Digital Content Editor, DDW
